Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Identification of surrogate endpoints in patients with locoregionally advanced nasopharyngeal carcinoma receiving neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone

Fig. 1

Survival curves for overall survival (OS), and potential surrogate endpoints. Kaplan–Meier survival curves of (a) OS and progression–free survival (PFS), (b) OS and failure–free survival (FFS), and (c) OS and distant failure–free survival (D-FFS) in the neoadjuvant chemotherapy followed by concurrent chemoradiotherapy (NACT+CCRT) group and CCRT alone group. Survival curves were truncated at 5 years. The numbers of patients at risk in each group are provided below the graph

Back to article page
\